arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Ceribell, Inc.

CBLL
$26.01 ▼ -1.30 (-4.76%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
4 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ceribell, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $950.5M
Dividend Yield —
Revenue Growth 36.1% ↘
Op. Margin -65.6% ↘
ROIC -37.6% ↘
FCF / Share $-1.14 ↗
Trailing P/E —
Price / Book 6.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

4-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$89.06M
↑ +36.1% —
Net Income Profit after all expenses
$-53.41M
↓ -32.0% —
Operating Margin Operating profit as % of sales
-65.6%
↓ -8.1% 4th
FCF / Share Free cash flow per share
$-1.14
↑ +62.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns
21
Financial Health ↓
21
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 16 quarters